|
Era
|
Prophylaxis
|
CMV disease, n (%)
|
Asymptomatic CMV infection, n (%)
|
No CMV, n (%)
|
|---|
|
1988–1991 (n = 59)
|
No
|
11 (19)
|
8 (13)
|
40 (68)
|
|
1992–1997 (n = 74)
|
Targeteda
|
11 (15)
|
17 (23)
|
46 (62)
|
|
1998–2000 (n = 32)
|
Targeteda
|
10 (31)
|
6 (19)
|
16 (50)
|
|
Total (n = 165)
| |
32 (19)
|
31 (19)
|
102 (62)
|
-
aTargeted prophylaxis given with 5 mg/kg of i.v. ganciclovir bid for 10 days in association with the first anti-rejection treatment with ATG and the second anti-rejection treatment with high-dose corticosteroids within the first 4 months post-transplantation
